about
Medical management of Parkinson's diseaseExploring Music-Based Rehabilitation for Parkinsonism through Embodied Cognitive ScienceMolecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidasesRegeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF.Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's disease.Endocannabinoid-dopamine interactions in striatal synaptic plasticity.Hydroxycinnamic acid amides from Scopolia tangutica inhibit the activity of M1 muscarinic acetylcholine receptor in vitro.Activation of group II metabotropic glutamate receptors induces long-term depression of excitatory synaptic transmission in the substantia nigra pars reticulataMonoamine oxidase-B inhibition in the treatment of Parkinson's disease.Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's diseaseEffect of Tianqi antitremor granules on behavioral manifestations and expression of G protein-coupled receptor kinase 6 and β-arrestin1 in levodopa-induced dyskinesia in a rat model of Parkinson's diseaseGlutamate receptors as therapeutic targets for Parkinson's disease.Polycyclic cage structures as lipophilic scaffolds for neuroactive drugs.Progress toward advanced understanding of metabotropic glutamate receptors: structure, signaling and therapeutic indicationsCholinergic and Dopaminergic Alterations in Nigrostriatal Neurons Are Involved in Environmental Enrichment Motor Protection in a Mouse Model of Parkinson's Disease.Therapeutic utility of phosphodiesterase type I inhibitors in neurological conditions.Part 2: Introduction to the Pharmacotherapy of Parkinson's Disease, With a Focus on the Use of Dopaminergic Agents.Computer-aided drug design applied to Parkinson targets.Oleic Derivatives of Dopamine and Respiration.Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson's disease.Antiparkinsonian Effects of Novel Adenosine A2A Receptor Antagonists
P2860
Q24647827-1170E9CA-AD01-4F00-8DDD-EEAB134038D1Q26779648-F7D3FFDA-1C4B-42CC-A221-E5648B68218CQ28475810-B369684B-C998-41DE-9E59-42779C4BF493Q34039452-43E467AF-3A63-4772-95FD-E4F101374CFDQ35776844-0482E23E-40A5-4438-B96F-AF9C62DC399FQ35898412-5CD6AFAF-77BE-4777-BE40-7CF7AF479A62Q36421337-02C404DC-B5DB-4DFF-8BC7-2089DEEF0DA1Q36566392-A443D479-D2E4-4366-AD84-180A5FA17764Q37016034-895B7A6D-3B93-4D71-92DD-4C614A4F8BDCQ37358676-27412511-CCCB-4AB0-BD40-704689218066Q37396700-AAD25D56-4295-4E11-90F3-3484208DF644Q37585401-9E2D40AD-8162-4985-AC12-02229D9C0E86Q37981634-C577B055-214C-4CEB-B5C5-110B8FE228E9Q38209092-3910A1CD-58D8-4AE8-87A1-AFFCE8643ACDQ39359668-BCAC1961-D34B-447B-8371-A93F000C1E3DQ41903612-AE8D4AFA-F04D-4107-80F9-93D3D00BF3FCQ43248920-1FFA880A-8204-454A-B5FB-2CC2515670D3Q47658773-FA0B72D6-7761-4ED0-A359-2A433707BEB9Q47841860-F0E4C4FE-A9A6-4E86-9AE2-95EB0F640AB4Q51442945-F305306C-00EA-4E64-884B-BA7D5FA0DFF9Q57708302-E32F0227-04DF-4DE8-A36A-FCABEE3B6988
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacotherapy for Parkinson's disease.
@en
Pharmacotherapy for Parkinson's disease.
@nl
type
label
Pharmacotherapy for Parkinson's disease.
@en
Pharmacotherapy for Parkinson's disease.
@nl
prefLabel
Pharmacotherapy for Parkinson's disease.
@en
Pharmacotherapy for Parkinson's disease.
@nl
P2860
P1433
P1476
Pharmacotherapy for Parkinson's disease
@en
P2093
Jack J Chen
P2860
P304
P356
10.1592/PHCO.27.12PART2.161S
P407
P433
P577
2007-12-01T00:00:00Z